SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update

SCYNEXIS advances pipeline with BARDA funding, but value realization remains years away.

What the company is saying

SCYNEXIS presents itself as a clinical-stage innovator targeting severe rare diseases, emphasizing the completion of Phase 1 studies for both SCY-770 and SCY-247. The company highlights a BARDA contract worth up to $214 million in non-dilutive funding, with $18.5 million committed initially, to support SCY-247’s development against invasive candidiasis. Management frames the SCY-770 program as a differentiated approach to ADPKD, citing tolerability at higher doses and plans for a Phase 2 trial by year-end, with interim analysis in late 2027. The narrative stresses a strong cash position ($63.2 million as of September 30, 2026) and a runway into 2029, while acknowledging increased R&D and SG&A expenses. Leadership changes are positioned as strengthening execution, with Sanjay Subramanian and Todd Minga joining as CFO and SVP R&D, respectively, and Steven Burke added to the board. The company also points to potential milestone payments of up to $146 million from GSK upon relaunch of BREXAFEMME, though this is contingent and not imminent.

What the data suggests

The company’s cash, cash equivalents, and investments declined from $71.1 million at June 30, 2026 to $63.2 million at September 30, 2026, reflecting ongoing development costs for SCY-770 and SCY-247. R&D expenses rose 14% year-over-year to $6.2 million, driven by a $1.7 million increase in clinical costs, partially offset by $0.6 million and $0.4 million decreases in preclinical and CMC expenses, respectively. SG&A expenses increased 8% to $3.6 million, mainly due to a $0.2 million rise in professional fees. The company reported $1.3 million in other income, up from a $0.2 million expense, primarily due to R&D tax credits. The BARDA contract provides up to $214 million in funding for SCY-247, but only $18.5 million is secured in the base period, with the remainder contingent on future milestones. SCY-770’s Phase 1 enrolled 25 participants and was well tolerated, but no efficacy data are disclosed. SCY-247’s Phase 1 IV trial enrolled 56 participants, with tolerability confirmed but no quantitative efficacy results. The company expects to initiate Phase 2 trials for both assets in late 2026 or 2027, subject to regulatory agreement. The potential for $146 million in annual milestones from GSK depends on the successful relaunch and sales of BREXAFEMME, with no timeline provided.

Analysis

The announcement is upbeat, highlighting the completion of Phase 1 studies, major government funding, and upcoming clinical milestones. However, most key value drivers—such as the initiation of Phase 2 trials for SCY-770 and SCY-247, and the potential for milestone payments from GSK—are forward-looking and will not materialize for at least 1-2 years. While the BARDA contract is a concrete achievement, the full $214 million is contingent and only $18.5 million is committed in the base period. The company’s cash burn is rising, and there is no disclosure of revenue, net income, or profitability metrics, which is typical for a clinical-stage biotech but limits the strength of the signal. Claims about tolerability and efficacy are not backed by detailed data. The tone is optimistic, but the gap between narrative and realised progress is moderate, with substantial capital outlays required before any commercial returns.

Risk flags

• ●Clinical execution risk is high: both SCY-770 and SCY-247 are pre-Phase 2, and efficacy in target populations is unproven. Failure to demonstrate efficacy or safety in upcoming trials would materially impair value.
• ●Funding risk remains: while the BARDA contract headline is $214 million, only $18.5 million is committed, with the remainder subject to future milestones and government discretion. Loss or delay of BARDA support would strain resources.
• ●Cash burn is rising: R&D and SG&A expenses increased year-over-year, and the cash position fell by $7.9 million in the last quarter. Although the company projects a runway into 2029, this assumes no major cost overruns or delays.
• ●Commercialization risk is substantial: the $146 million in potential GSK milestones is contingent on the relaunch and strong sales of BREXAFEMME, with no certainty or timeline. There is no current revenue from these milestones.
• ●Regulatory risk is present: both Phase 2 programs require regulatory agreement before initiation, and any delay or negative feedback could postpone value realization.

Bottom line

SCYNEXIS has secured significant non-dilutive funding and advanced its pipeline, but all major value drivers—clinical efficacy, regulatory progress, and commercial milestones—are at least 1–2 years away. The company’s rising R&D and SG&A expenses are eroding its cash position, though management claims a runway into 2029. The BARDA contract headline is large, but only a fraction is currently committed, and future tranches depend on continued progress. No efficacy data from Phase 1 trials are disclosed, and all clinical claims remain unproven in patients. The GSK milestone opportunity is speculative and tied to events outside SCYNEXIS’s control. Investors should focus on the initiation and results of Phase 2 trials as the next real inflection points; until then, the story is one of potential, not realized value.

Announcement summary

(NASDAQ: SCYX) SCYNEXIS, Inc. reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. The company completed a Phase 1 study of SCY-770, a selective and direct AMPK activator, enrolling 25 healthy participants across three cohorts with dosing regimens of 500 mg single dose, 750 mg once daily, or 500 mg twice daily, or placebo for seven days. SCY-770 was well tolerated at higher doses than previously evaluated, and pharmacokinetic and safety data will inform dose selection for the planned Phase 2 trial in Autosomal Dominant Polycystic Kidney Disease (ADPKD). SCYNEXIS plans to initiate the Phase 2 proof-of-concept study of SCY-770 in ADPKD patients in Q4 2026, with an interim analysis anticipated in Q4 2027. The company was awarded a BARDA contract providing up to approximately $214 million in non-dilutive funding, with $18.5 million in the initial base period, to advance the development of SCY-247 for invasive candidiasis. The BARDA award is structured as a cost-share arrangement, and SCYNEXIS expects to fund its share of near-term program costs for SCY-247 within its existing operating plan. On October 22, 2026, SCYNEXIS announced topline results from its Phase 1 single and multiple ascending dose trial of intravenous SCY-247 in 56 healthy participants, showing that IV SCY-247 was generally well tolerated, with no drug-related serious adverse events, and once-daily IV doses of 50 mg or higher achieved exposures at or above the efficacy target identified in murine models. The company expects to initiate Phase 2 development of SCY-247 in oral and IV formulations in 2027, subject to regulatory agreement. SCYNEXIS believes GSK continues making progress toward the relaunch of BREXAFEMME, and following the relaunch, SCYNEXIS has the potential to receive up to approximately $146 million in annual net sales milestones as well as net royalties in the low to mid-single digit range. Leadership changes include the appointment of Sanjay S. Subramanian, MBA, as Chief Financial Officer effective September 9, 2026, succeeding Ivor Macleod, and Todd Minga, M.D., as Senior Vice President, Research & Development effective September 14, 2026. Steven K. Burke, M.D., was appointed to the Board of Directors effective September 18, 2026, and serves on the Nominating and Corporate Governance Committee. Research and development expenses for the three months ended September 30, 2026, were $6.2 million compared to $5.5 million for the same period in 2025, an increase of $0.7 million or 14%, primarily driven by a $1.7 million increase in clinical expense, offset by a $0.6 million decrease in preclinical expense and a $0.4 million decrease in chemistry, manufacturing, and controls expense. SG&A expenses for the three months ended September 30, 2026, increased to $3.6 million compared to $3.3 million for the same period in 2025, an increase of $0.3 million or 8%, primarily due to a $0.2 million increase in professional fees. Total other income was $1.3 million for the three months ended September 30, 2026, versus total other expense of $0.2 million for the same period in 2025, mainly due to other income recognized for certain research and development tax credits. Cash, cash equivalents and investments totaled $63.2 million on September 30, 2026, compared to $71.1 million on June 30, 2026, with the decrease primarily due to continued development costs for SCY-770 and SCY-247. This cash position is expected to be sufficient to continue operations into 2029. ADPKD affects about 140,000 people in the United States, with approximately 6,000 new cases diagnosed each year, and more than 50% of patients reach end-stage renal failure by age 60. Jynarque (tolvaptan), the only approved therapy for ADPKD, achieved approximately $1.5 billion in U.S. sales in 2024. SCY-770 has been evaluated in approximately 300 participants to date and has been granted Orphan Drug Designation by the U.S. FDA. SCY-247 has been granted Orphan Drug, Qualified Infectious Disease Product (QIDP), and Fast Track designations by the U.S. FDA. The BARDA contract for SCY-247 is under contract number 75A50126C00007.

Disagree with this article?